Provided by Tiger Fintech (Singapore) Pte. Ltd.

I-MAB

0.6800
-0.0501-6.86%
Post-market: 0.77000.0900+13.24%19:58 EDT
Volume:585.98K
Turnover:378.15K
Market Cap:55.38M
PE:-0.89
High:0.7000
Open:0.6801
Low:0.5950
Close:0.7301
Loading ...

I-Mab Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
04 Apr

I-Mab expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
04 Apr

BRIEF-I-Mab Reports Full Year 2024 Financial Results

Reuters
·
04 Apr

I-MAB FY24 Adj EPADS $(0.27) Up From $(2.50) YoY

Benzinga
·
04 Apr

I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

THOMSON REUTERS
·
04 Apr

Press Release: I-Mab Reports Full Year 2024 Financial Results and Provides Business Update

Dow Jones
·
04 Apr

I-Mab expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
31 Mar

I-Mab to Present at 24th Annual Needham Virtual Healthcare Conference

GlobeNewswire
·
26 Mar

I-Mab Gets Nasdaq Noncompliance Notice on Bid Price Requirement

MT Newswires Live
·
22 Mar

BRIEF-I-Mab gets Nasdaq notice regarding minimum bid price requirement

Reuters
·
22 Mar

I-Mab Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

THOMSON REUTERS
·
22 Mar

I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

GlobeNewswire
·
22 Mar

I-Mab expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
21 Mar

I-Mab expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
11 Mar

I-Mab announces accelerated givastomig Phase 1b study progress

TIPRANKS
·
07 Mar

BRIEF-I-Mab Announces Accelerated Givastomig Phase 1B Study Progress

Reuters
·
07 Mar

I-Mab: Phase 1B Dose Escalation Data Expected to Be Presented in 2H 2025

THOMSON REUTERS
·
07 Mar

I-Mab: Topline Results From 40-Patient Dose Expansion Study Expected in 1H 2026

THOMSON REUTERS
·
07 Mar

I-Mab Announces Accelerated Givastomig Phase 1B Study Progress

THOMSON REUTERS
·
07 Mar

I-Mab Announces Accelerated Givastomig Phase 1b Study Progress

GlobeNewswire
·
07 Mar